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Abstract: Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, 
peptidomimetic protease inhibitor (PI) with a modified 3-dimensional structure enabling more 
efficient binding to HIV protease. It has become an important drug, in combination with low-dose 
ritonavir boosting, in the treatment of both antiretroviral-naïve and multiclass-experienced 
patients. Growing data now exist suggesting it possesses a high barrier to resistance and requires 
multiple PI mutations in order to suffer reduced virological potency.
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Since the approval of saquinavir in 1995, the protease inhibitor (PI) class has served an 
important role in constructing an effective highly active antiretroviral combination for 
patients with HIV .1 The PIs have several advantages over alternatives: they generally 
require greater numbers of resistance mutations to occur before they are rendered 
virologically ineffective (a property referred to as having a higher genetic barrier to 
resistance), and have not had the mitochondrial toxicities seen with some other agents. 
They have limitations, however, both in terms of their side effect profiles, and the 
cross resistance often inferred when PI mutations accumulate.2,3
Darunavir (DRV) represents a specifically engineered inhibitor of HIV-protease, 
designed to have a greater binding affinity within the active site of the viral enzyme.4 
DRV requires co-administration with low-dose ritonavir (RTV) to achieve sufficiently 
concentrations for anti-HIV activity. On the basis of favorable results from a number 
of phase IIb clinical trials (described below), the US FDA granted ‘accelerated 
approval’ for DRV in June 2006, followed shortly after by European authorities in 
February 2007. It was subsequently approved for use in HIV-infected, antiretroviral-
naïve patients.
Structural determination of substrate binding 
to HIV-protease
During viral maturation, HIV protease acts to cleave the post-translational proteins Gag 
and Gag-Pol to generate additional functional enzymes and structural proteins.4 This 
process is essential to achieve successful viral replication, thereby making protease an 
excellent target for antiretroviral agents. All approved PIs are competitive active-site 
inhibitors, and as such, would ideally mimic the enzyme substrate ensuring it interacts 
with the same residues on protease.5HIV/AIDS - Research and Palliative Care 2009:1 14
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Although structurally similar to amprenavir (see 
Figure 1), DRV has significantly greater binding avidity 
(Kd = 4.5 × 10–12 M), binding over 100 times tighter, and over 
1000 times tighter than ritonavir, saquinavir or nelfinavir.6 The 
uniquely strong binding, and concurrent slow dissociation, 
are in part due to a complex of hydrogen bonds between a 
side chain on DRV and protease, similar to that found on 
native substrates. To illustrate this point, the mutation I84V 
is one of the most common PI mutations affecting the class 
as a whole. Although DRV binding affinity was affected in 
mutants harboring I84V , it was still at least 1.5 times stronger 
than all previous PI medications. Additionally, there is a 
second binding site on the protease surface of a V32I drug-
resistant mutant that confers additional activity for DRV , in 
contrast to older agents.7 The second site is on the surface 
of a flexible flap in the protease dimer. DRV also has some 
molecular flexibility, and can therefore adapt to varying 
shapes presented by mutant HIV-protease.8
In vitro efficacy
Preclinical studies revealed DRV to be a highly potent against 
HIV replication, in both wild-type and resistant viruses. DRV 
has a potent 50% effective concentration (EC50) of 1 to 5 nM, 
and an EC90 of 2.7 to 13 nM, considerably lower than typical 
human concentrations, whereas there is no demonstrable cyto-
toxicty at 100 µM (selectivity 20,000).9 Additionally, 50% 
inhibitory concentration data (IC50) suggests far greater efficacy 
compared to previous PIs: DRV IC50 = 0.003 µM, compared 
to a range of 0.017 to 0.047 µM for saquinavir, amprenavir, 
indinavir, lopinavir, and ritonavir.10 Efficacy appears similar 
between HIV group M, group O, and recombinant forms. DRV 
also has potent activity in vitro against HIV-2.10
Pharmacokinetic profile
Darunavir has relatively poor bioavailability, metabolized 
primarily by the hepatic cytochrome P450 enzyme CYP3A4. 
Although there is a significant first pass effect, ‘boosting’ 
doses of RTV are used clinically to increase bioavailability 
from 37% to 82%, and thus extend the elimination half-life to 
almost 15 hours. DRV concentrations in blood are increased 
by 30% when given with food, although the fat content of 
the meal does not seem to affect final concentrations.11 It is 
95% protein bound in plasma, primarily to the alpha 1-acid 
glycoprotein, and achieves peak plasma concentration (Cmax) 
in roughly 3 hours.12
Dose-ranging studies indicated that DRV 600 mg, given 
with 100 mg RTV , both twice daily, was the best combination 
of antiviral activity and diminished toxicity. It was selected 
for further study and became the initial licensed dose.
DRV is also distributed to compartments other than blood, 
achieving CSF concentrations sufficient to inihibit viral 
replication.13 Achievable drug levels in genital secretions 
are currently being assessed.
Important clinical studies
The first proof-of-concept trial for DRV was a 14-day 
multicenter trial of 3 boosted doses of DRV/ritonavir (DRV/r) 
(300/100 mg twice daily, 900/100 mg daily, and 600/100 mg 
twice daily) compared to a standard optimized background 
regimen.14 In the 50 patients studied, an HIV viral load less 
than 400 copies/mL was achieved in 46%, 31%, 42%, and 
8% of patients, respectively, along with CD4 count improve-
ments of 16, 5, 63, and 0.5 cells/µL. No DRV resistance was 
identified during this brief period.
POWER 1 and 2 trials
Initial phase IIb clinical trials assessed the activity 
of darunavir given with an optimized background 
regimen in HIV-infected patients with extensive prior 
antiretroviral treatment and multiclass resistance. POWER 1 
(TMC114-C213) and POWER 2 (TMC114-C202) were 
both multinational partially blinded randomized controlled 
salvage trials. Inclusion criteria were similar across the 
two studies – treatment-experienced adults with an HIV 
viral load 1000 copies/mL, and at least one primary PI 
mutation. Both studies were conducted simultaneously in 
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Figure 1 The structural similarity of darunavir (left) and amprenavir (right).HIV/AIDS - Research and Palliative Care 2009:1 15
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different geographical areas, and contained 2 parts – an 
initial phase II dose-finding phase followed by a long-term 
phase in which participants either received boosted DRV or 
an investigator-selected comparator protease inhibitor. The 
primary efficacy endpoints in the POWER 1 and POWER 2 
trials were the proportions of patients achieving a 1 log10 
reduction from baseline viral load. Secondary endpoints 
included changes from baseline CD4 count and the propor-
tion of patients who achieving an undetectable HIV viral 
load (VL  50 copies/mL). Mean VL were 4.66 (DRV) 
and 4.48 log10 c/mL (comparator) respectively, and base-
line CD4 counts were 106 and 179 cells/µL.15 The interim 
analysis conducted at 24 weeks led to the eventual selection 
of DRV/r 600/100 mg twice daily as the dose selected for 
further clinical evaluation.
At closure (144 weeks), combined analysis of POWER 1 
and 2 confirmed the prolonged activity of DRV in HIV-
infected treatment-experienced patients, 51% of DRV 
recipients sustaining virologic suppression of 1 log10 
(n = 131) compared to 10% of those on an optimized 
background therapy (OBT) (n = 124). Thirty-seven 
percent of those on DRV achieved a viral load less than 
50 copies/mL, compared to 9% of those receiving OBT. 
Immunologically, the treatment group achieved a 97 cell/mL 
increase compared to a 4 cell/mL increase (last observation 
carried forward analysis).16 Of note, at the time of the 
study tipranavir, raltegravir, maraviroc, and etravirine 
were not available. (enfuvirtide [T-20] was available at the 
investigator’s discretion).
The use of enfuvirtide was associated with higher rates of 
viral suppression reflective of the importance of using more 
than one active agent in DRV regimens. With enfuvirtide 
first-time use, pooled data showed 56% of those in the DRV 
arm achieved a viral load 50 copies/mL at 48 weeks, versus 
45% with no enfuvirtide. Without enfuvirtide this was still 
a satisfactory but clearly reduced 45%. Importantly, if only 
those patients with no pre-existing DRV-associated resis-
tance mutations (DRV-RAMS) were studied, the addition of 
enfuvirtide made no difference. Additionally, there is likely a 
selection bias among those given enfuvirtide, as evidenced by 
the fact that enfuvirtide recipients had a lower CD4 count at 
baseline with fewer active NRTIs in their background. Thus 
a true comparison is difficult to make.17
POWER 3
POWER-3 (TMC-114-C215) was an open-label safety 
and efficacy study in 327 patients, intended to expand the 
population of DRV patients for adverse events assessment. 
In this similarly Caucasian male-dominated study, with 
similar inclusion criteria as POWER 1 and 2, mean base-
line log10 HIV RNA = 4.58 copies/µL, median CD4 cell 
count = 120 cells/mm3, CDC category C = 55%, and median 
number of primary PI mutations = 4.18,19 Using a TLOVR 
algorithm, 32% achieved a viral load of 50 copies/mL at 
week 144.
TITAN
The first direct head-to-head comparison of PI efficacy 
involving darunavir came with the phase III TITAN trial 
(TMC144-C214). TITAN was an open-label study comparing 
lopinavir/ritonavir (LPV/r) with DRV/r (600/100 mg twice 
daily) in patients with moderate previous PI experience.20 
Geometric mean fold change (FC) was similar in both groups 
at randomization, although 58 patients had a LPV FC  10, 
compared to just 9 with DRV . There were also more patients 
in the DRV group with 2 sensitive backbone ARVs used 
(non-PI), 203 (73%) compared to 181 (63%). Whether this 
affected the conclusion is unclear. After 96 weeks of treatment 
DRV was noninferior to LPV , the primary end-point of the trial 
(DRV = 67.5% to LPV = 59.5% achieving VL  400 copies/
mL, P  0.001). In fact, DRV was superior to LPV based 
on a pre-defined end-point analysis (P = 0.034). Rates 
of virologic failure, as assessed by inability to suppress 
VL  400 copies/mL by week 16 or viral rebound above 
400 copies/mL after initial suppression, was greater in the 
LPV arm, 25.6% vs 13.8%. Data from the TITAN and the 
POWER studies led to accelerated approval of darunavir for 
use in treatment-experienced patients.
ARTEMIS
Based on observed response rates to DRV in patients with 
moderate prior PI exposure in the TITAN trial, the natural 
extension was to test efficacy in treatment-naïve patients. The 
ARTEMIS trial was a phase III open-label trial randomizing 
people to DRV/r 800/100 mg once daily or LPV/r 800/200 mg 
daily dose (given either twice daily [bid] or daily [qd]). 
689 patients were randomized; trial participants began 
treatment with an average VL of about 4.85 log10 (70,000 
copies) and a median CD4 count of 228 in the DRV group 
and 218 in the lopinavir (LPR) group. About 60% in each 
treatment arm had subtype B virus, and fewer than 10% in 
each arm had AIDS. At 48 weeks DRV/r was not inferior to 
LPR/r, with 84% of the DRV/r group achieving a VL  50 
copies, compared to 78% in the LPV group. Response rates 
for those with baseline VL  100,000 were better in the DRV 
arm (79% vs 67% response, P  0.05), as were responses in HIV/AIDS - Research and Palliative Care 2009:1 16
Wolfe and Hicks Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
those with baseline CD4 count 200 cells/µL. DRV efficacy 
seemed to be independent of any individual variation in 
pharmacokinetics.21
Longer term follow-up (through to 96 weeks) confirmed 
the initial results: 79% of DRV patients had achieved a 
VL  50 copies/mL compared to 71% receiving LPV 
(difference = 8.3%, P value for superiority = 0.012, 
ITT-TLOVR).22 Interestingly suboptimal adherence (based 
on self-reporting using a validated questionnaire) appeared 
to affect DRV responses less than LPV response (7% vs 25% 
difference compared to adherent patients, respectively).
Other studies
In pediatric populations, DRV/r has similar efficacy. The 
DELPHI study (TMC114-C212) was an open-label phase II 
study of treatment-experienced HIV-1-infected patients 
between the ages of 6 and 17 years. Dosing was weight-
based: either 375/50 mg bid (44 to 66 lbs [20 to 30 kg), 
450/60 mg bid (66 to 88 lbs [20 to 40 kg) or 600/100 mg bid 
(weight  88 lbs [40 kg]). Mean age was 14 years, mean 
CD4 count was 330 cell/µL and mean VL = 4.64 log10. 
At 24 weeks VL  50 copies was achieved in 50% of the 
population, and less than 400 copies in 64%. Average CD4 
count increase was 117 cells/µL. Pharmacokinetic results 
were similar to adults, and the drug was generally well 
tolerated.23 DRV was approved for use in pediatric popula-
tions in December 2008 in the US.
Additional research will illuminate treatment responses 
in other populations. The GRACE trial (TMC114HIV3004) 
is focused on DRV responses among women and ethnic 
minorities. The ODIN trial (TMC114-C229) hopes to expand 
on preliminary information suggesting 800/100 mg DRV/r 
given once daily is effective even in treatment-experienced 
patients provided they have no specific DRV mutations. 
Pilot studies have already been completed24 and subanalysis 
of POWER data suggests the approach worthy.25 Currently, 
following the TITAN and POWER studies the 600/100 mg 
bid dosing is still recommended. In line with similar studies 
from older PIs, the MONET trial is taking patients with well 
controlled HIV (VL  50 copies/mL for at least 24 weeks 
and randomizing them to receive triple-drug therapy includ-
ing DRV , or 800/100 mg DRV/r monotherapy.
Drug resistance
Initial in vitro viral passage studies suggested mutants show-
ing resistance to darunavir evolved slowly,9 and were difficult 
to predict. Subsequent clinical trials have attempted to quan-
tify which preexisting mutations were likely to deleteriously 
impact on darunavir efficacy. Data from the POWER studies 
and the DUET trials (of etravirine) helped generate a list of 
DRV-RAMS. The International AIDS Society (IAS-USA) 
currently lists 11 major mutations for darunavir: V11I, V32I, 
L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, and L89V. 
Of these I50V, I54M/L and I84V have been identified as 
major mutations, referring to their tendency to be selected 
earlier in the presence of DRV or substantial reduction of 
DRV susceptibility. Mutations in the protease flap region are 
recognized as critical for modified binding of a number of PIs. 
This explains, for example, the observed clinical darunavir 
resistance noted with I50V which forms part of this region.26 
Interestingly, when many of the other DRV-RAMs were 
included in a wild-type genetic background by site-directed 
mutagenesis, they did not cause decreased susceptibility to 
DRV, suggesting numerous additional PI mutations were 
required for resistance.27
There have been suggestions that some patients harboring 
the amprenavir-specific resistance profiles, such as I50V or 
V32I + I47V , failed on a DRV/r-containing therapy.28 Larger 
analysis of the POWER studies showed among patients with 
a high level of phenotypic resistance to (fos)amprenavir 
(FC  11.4), response to DRV/r was lower than those 
with a high level of phenotypic resistance (31% to 66% 
at 48 weeks). Despite this there was no association with 
previous (fos)amprenavir use and DRV failure per se.29
The number of baseline primary PI mutations, as 
identified by the IAS-USA had minimal effect on viro-
logic outcomes, as patients with 0 mutations in the 
TITAN trial achieved suppression in 84% (139/165) as 
did patients with 3 baseline mutations.20 There does, 
however, appear to be a strong correlation with the 
number of DRV-specific RAMs, 3 being associated 
with a DRV FC  10, and therefore a less favorable 
outcome.17 When stratified according to phenotypic FC, 
an FC  10 from baseline resulted in viral load reduction of 
2.08 log10 copies/mL, an FC = 10 to 40 resulted in decrease 
of 1.08 log10 copies/mL, and an FC  40 resulted in only 
a 0.76 log10 copies/mL. Proportions of patients achiev-
ing an undetectable VL were 50%, 25%, and just 13% 
respectively. Within the POWER studies, the proportion 
of patients achieving a RNA VL  50 copies/mL declined 
as the number of RAMs increased: 60% with zero RAMs, 
45% with 1 to 2 and 20% with 3 or more.
More recently, a number of other mutations have been 
detected, following a multivariate analyses of 153 French 
patients receiving salvage DRV/r, although these have not 
been added to the IAS-USA DRV RAM list.30HIV/AIDS - Research and Palliative Care 2009:1 17
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As clinicians begin to use DRV/r earlier in treatment 
of HIV-infected patients, concerns remain as to future PI 
susceptibility in those experiencing virologic failure. Trial 
data of those failing initial DRV-containing regimens sug-
gest few new resistance mutations develop. By week 48 in 
ARTEMIS, patients experiencing viral rebound had not 
developed any IAS-USA PI resistance mutations,31 although 
one NRTI mutation was noted, M184V . In the POWER stud-
ies, those with virologic failure were noted to have a small 
number of mutations already recognized as DRV-RAMs 
(V32I, L33F, I47V , I54L, and L89V). Similar results were 
seen in the French cohort with the addition of V11I, and 
I50V , also both contained within the most recent IAS-USA 
list of DRV mutations.32
The sparsity of mutagenesis in those failing DRV-
containing regimens suggests that, as with other PIs, virologic 
failure tends to be associated with poor adherence. In the 
absence of preexistent DRV resistance, newly acquired 
DRV-RAMs were also rare. Certainly DRV/r appeared to 
spare future PI use more so than LPV/r in the TITAN trial, 
as seen in Figure 2.
Baseline tipranavir susceptibility was maintained in 
a number of studies, despite DRV virological failure, 
suggesting it will remain an option, even in the heavily 
treatment-experienced population.32,33 This may possibly be 
because of the 21 recognized tipranivir resistance mutations, 
only 5 (V11I, V33F, I47V, I54M, and I84V) are also 
DRV-RAMs.8,34 Conversely 70% of isolates seen to have 
dimished tipranavir susceptibility still retained susceptibility 
to DRV . Further clinical data on the resistance development 
in the antiretroviral-naïve population using DRV will 
help verify the absence of resistance in most persons with 
virologic failure.
Presentation
DRV is packaged as a direct compression tablet, now pro-
duced in the US as either a 400 mg or 600 mg formulation 
(the 300 mg dose is no longer available). A smaller 75 mg 
tablet has been released to dovetail with the approval in 
pediatric populations. Dosing for adults should at present be 
600/100 mg bid with RTV for treatment-experienced adults, 
or 800/100 mg daily for treatment-naïve adults. Pediatric 
doses vary with weight, as shown in Table 1. A liquid for-
mulation is currently under investigation. Similar dosing is 
recommended for all patients irrespective of renal function, 
although data are limited for hemodialysis, hemofiltration, 
or peritoneal dialysis. Dosing guidelines for patients with 
severe hepatic impairment suggest caution.
Safety
In clinical trials DRV/r has been generally well tolerated. The 
most significant adverse event has been hepatotoxicity, such 
that the FDA released an official warning in March 2008. 
The incidence of significant hepatotoxicity is about 0.5% 
in clinical trials. Although the more common abnormalities 
have been acute hepatitis and cytolytic hepatitis, rare fulmi-
nant cases and a number of deaths have occurred, although 
generally in patients with advanced disease who were taking 
multiple concominant medications. A substudy of patients 
co-infected with hepatitis B and/or C within the POWER 
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Figure 2 Percentage of patients in whom pretreatment isolates that were susceptible to protease inhibitors remained so after failure of darunavir/ritanovir (DRV/RTV) or 
lopinavir/ritanovir (LPV/RTV) in the TITAN trial.  Drawn from data of de Meyer.35HIV/AIDS - Research and Palliative Care 2009:1 18
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trials showed more coinfected patients to have liver-relatied 
adverse events compared to their mono-infected counterparts, 
although numbers were small.37 Rates were similar in those 
receiving DRV or the investigator selected PI. Whether 
adverse hepatic events occur more frequently in those with 
severe hepatic synthetic impairment or in those who develop 
immune reconstitution inflammatory syndrome remains to 
be determined.36
In the major DRV trials, rates of side effects were 
generally low. Rash is one of the most common (16% to 
7% compared with LPV in TITAN), most likely due to the 
sulfonamide moiety with DRV . Reassuringly 1% of users 
developed a severe or life-threatening rash (Stevens-Johnson 
syndrome), with a 0.3% discontinuation rate due to rash. 
Only 7% of patients receiving DRV discontinued for any 
reason.38 Gastrointestinal (GI) adverse events of any kind 
occur less than frequently than LPV (75% vs 61%). In the 
POWER studies, the most common adverse events (10% 
regardless of severity or causality) were diarrhea, headache, 
nausea, and fatigue.15,16 Reported GI events occurred in 7% 
of adherent patients compared to 28% of the suboptimally 
adherent.
Longer-term safety profiles of antiretroviral agents are 
increasingly important as patients stay on medications longer. 
Occasional lipodystrophy, hyperlipidemia. and worsening 
insulin resistance have been reported. Triglyceride levels 
and total cholesterol rose in the ARTEMIS cohort although 
less with DRV than with LPV , as may have been expected. 
Findings were equivalent for elevations in mean low-density 
lipoprotein and total cholesterol/high-density lipoprotein 
ratio.31 Small weight gains were seen in trial patients; how-
ever, there were no associated with changes in body shape 
and it was difficult to distinguish between change likely from 
general health restoration.31
There have been no adequate and well controlled studies 
in pregnant women. DRV therefore is currently classified as 
a Category C drug, because animal data in which there was 
no detected teratogenicity in mice, rabbits, and rats. It is 
passed into breast milk.
Drug interactions
Especially because DRV needs RTV boosting, there are a 
number of significant drug interactions to consider. These 
are generally applicable across the majority of the PIs. 
Rather than a comprehensive list, a selection of important 
or life-threatening interactions is presented in Appendix 1.36 
One interaction that deserves special attention is that of 
DRV/r with rifampin. Coadministration leads to a marked 
decrease in plasma DRV levels that in turn may lead to 
a loss of therapeutic effect. RTV does not overcome this 
interaction, and hence the combination is not recommended. 
Given the importance of the rifamicins in the treatment of 
Mycobacterium tuberculosis, substitution with rifabutin is 
usually recommended. DRV/r conversely increases the AUC 
and Cmax of rifabutin, so it should be dosed at 150 mg every 
Monday/Wednesday/Friday.
Clinical roles of darunavir
As with most drugs approved in the last 5 years, DRV was 
first shown to be efficacious in highly treatment-experienced 
patients. Subsequently studies have shown efficacy with 
once daily dosing, including children and treatment-naïve 
patients. Its tolerability, dosing flexibility, high potency, 
and favorable resistance characteristics have made it an 
increasingly popular drug for HIV-infected person in all 
states of infection. As with all antiretroviral agents, DRV/r 
should be given with other fully active drugs based on resis-
tance testing. Fortunately several new antiretroviral agents 
have become available recently. Raltegravir, the first HIV 
integrase inhibitor, seems to work well with DRV/r. In the 
BENCHMRK studies, approximately 60% of the patients 
received DRV/r as part of their optimized background, and 
subgroup analysis of those patients revealed especially high 
response rates.39,40
Similarly in the DUET trials of etravirine, DRV was 
frequently used as part of an optimized background.41 
Combinations of newer antiretroviral agents have proven to 
be quite efficacious. In a small cohort of 103 French patients, 
with triple-class experience, the combination of DRV/r, 
etravirine and raltegravir did especially well.42 Fifty-five 
percent of this highly resistant group had an undetectable 
VL by week 4, and 93% by week 24 had VL  50 copies/mL. 
CD4 lymphocytes increased to a mean of 99 cells/µL, and 
only 1 patient discontinued the regimen (due to rash). 
Further ‘real world’ clinical studies using combinations of 
Table 1 Recommended dose for pediatric patients (6 to 18 years 
of age) for Prezista® tablets with ritonavir body weight dose36
Body weight   Dose
(kg) (lbs)
20 kg to 30 kg 44 lbs to 66 lbs 375 mg darunavir/50 mg 
ritonavir twice daily
30 kg to 40 kg 66 lbs to 88 lbs 450 mg darunavir/60 mg 
ritonavir twice daily
40 kg 88 lbs 600 mg darunavir/100 mg 
ritonavir twice dailyHIV/AIDS - Research and Palliative Care 2009:1 19
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the newer agents will be required, but for now, these results 
are encouraging.
In the antiretroviral-naïve patient, DRV/r 800/100 mg 
now offers an alternative as a first-line PI regimen. Advan-
tages are a relatively low pill burden and an excellent profile 
for efficacy, resistance, and safety. Co-administration with 
ritonavir remains problematic with DRV as with other PIs, 
for many reasons – RTV for many is burdensome in terms of 
its capsule size, need for refrigeration, complex drug–drug 
interactions, and GI side effects.
Conclusion
Darunavir, a recently approved HIV protease inhibitor, offers 
clinicians an important option for the treatment of treatment-
naïve and -experienced patients. It has a favorable side effect 
profile, is accordingly well tolerated, and has shown excellent 
capacity to suppress HIV viral load and engender CD4 cell 
recovery. Importantly, resistance to darunavir is relatively 
uncommon, facilitating prolonged efficacy in patients.
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Appendix 1 Interactions with darunavir/ritonavir36,43
Drug class Drug of concern Interaction
Anti-infectives rifampicin Reduced DRV levels, avoid
rifabutin Increased rifabutin levels and toxicity; recommended 
rifabutin dose reduction to 150 mg every other day
voriconazole Significant decrease in voriconazole level expected 
with DRV/r – must use with caution and possible 
use therapeutic drug monitoring of voriconazole; 
individually, 39% reduction and 24% reduction in 
voriconazole dose with DRV and RTV respectively
fluconazole No significant interaction
itraconazole/ketaconazole Increased azole and DRV levels
halofantrine/lumafantrine Avoid – increased risk of prolonged QTc via reduced 
P450-3A4 metabolism
Cardiovascular medication amiodarone Increased levels of amiodarone expected, watch for 
cardiac arrhythmia
lidocaine (lignocaine) Increased levels of lidocaine expected, watch for 
cardiac arrhythmia
warfarin Reduced warfarin exposure (21% following a single 
dose), should check INR levels more frequently
CCB, BBs Potential increase in most CCB and BBs
Lipid-lowering agents statin class Increased levels of most statins (reduced metabolism 
via 3A4); avoid simvastatin, caution and possible dose 
reduction with pravastatin/atorvastatin
Immunosuppressants cyclosporin/tacrolimus/sirolimus expected increased levels of immunosuppressant – 
recommend therapeutic drug monitoring
Psychotropics SSRI Generally reduced SSRI levels, watch therapeutic 
response
respiridone/clozapine/haloperidol Increased psychotropic levels, watch therapeutic 
response
erectile dysfunction sildenafil/vardenafil Increased levels, suggest lower doses
Illicit drugs amphetamines, gamma-hydroxybutyrate Increased levels and possibly toxicity from illict agents
Herbals St John’s wort Decreased DRV levels.   Avoid. Prolonged effect even 
after discontinuation
Antiretrovirals maraviroc Complex interaction – expected 4 × increase in 
AUC and 2.3 × increase in Cmax of maraviroc, but 
recommend careful review of all medications
Contraceptives ethinylestradiol/norethindrone Significant decreased levels – recommend seek 
alternative contraceptive methods
Anticonvulsants phenytoin, phenobarbital Decreased concentrations of anticonvulsants and 
DRV; avoid if possible
Abbreviations: AUC, area under the curve; BB, beta-blockers; Cmax, maximum concentration; CCB, calcium-channel blockers; DRV, darunavir; INR, international normalized 
ratio; RTV, ritanovir; SSRI, selective serotonin reuptake inhibitors.